VALERIE ARCHER: Open Payments
NPI 1881240216 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,534 in 109 payments from 16 companies in 2025. Trend: 2023 $1,177 · 2024 $1,924 · 2025 $2,534
Food & beverage: $2,430Education: $104
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 23 | $461 |
| Otsuka America Pharmaceutical, Inc. | 26 | $438 |
| Neurocrine BioSciences, Inc. | 10 | $366 |
| Alkermes, Inc. | 13 | $350 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $241 |
| ABBVIE INC. | 7 | $221 |
| Teva Pharmaceuticals USA, Inc. | 5 | $183 |
| Janssen Pharmaceuticals, Inc | 3 | $78 |
| ACADIA Pharmaceuticals Inc | 2 | $38 |
| Bausch Health US, LLC | 2 | $38 |
Products named: COBENFY, REXULTI, INGREZZA, ARISTADA, CAPLYTA, VRAYLAR, SPRAVATO, AUSTEDO XR.
Industry payments across NV — which companies pay providers there.
